LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)
Status:
Not yet recruiting
Trial end date:
2025-07-30
Target enrollment:
Participant gender:
Summary
Early fetal growth restriction (FGR) is associated with considerable fetal and neonatal
morbimortality (Miller et al. 2008, Nardozza et al. 2017). Placental thrombosis, infarcts and
hypercoagulability are frequently seen in these pregnancies, suggesting a role for the
activation of the coagulation cascade in the genesis of FGR. Patients will be randomized for
low-molecular weight heparin or standard of care, and the outcomes of both arms (gestational
age at delivery, gestational and fetal morbidity) will be compared.